FIELD: medicine; oncology; immunology.
SUBSTANCE: group of inventions is intended for eliciting an immune response to an antigen, such as antigens of malignant tumors and microorganisms. Device for modulating the immune response contains a framework composition containing mesoporous silica rods. Said framework composition has a polyethyleneimine (PEI) modified surface. Said framework composition contains open interconnected macropores or is a pore-forming framework composition. In another embodiment, a method of treating a malignant tumor in a subject in need thereof is disclosed, involving the introduction of said device. Also disclosed is a method of increasing immunogenicity of antigen, involving combining antigen with PEI in said device.
EFFECT: use of the group of inventions enables to increase the antigen immunogenicity.
29 cl, 35 dwg, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC ANTI-CANCER NEOEPITOPE VACCINE | 2017 |
|
RU2782422C2 |
| METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING MALIGNANT TUMOUR | 2016 |
|
RU2718499C2 |
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| ANTIBODIES BINDING CTLA-4 AND APPLICATION THEREOF | 2018 |
|
RU2756100C1 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| MULTIVALENT AND MULTI-SPECIFIC 41BB-BINDING FUSED PROTEINS | 2017 |
|
RU2789648C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
